DK0925069T3 - Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer - Google Patents

Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer

Info

Publication number: DK0925069T3
Authority: DK; Denmark
Prior art keywords: cetrorelix; treatment; prostate; hypertrophy; prostate cancer
Prior art date: 1996-09-12

Application number

DK97944818T

Other languages

English (en)

Inventor

Juergen Engel

Thomas Reissmann

Hilde Riethmueller-Winzen

Juergen Rawert

Original Assignee

Aeterna Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1997-09-01

Publication date

2007-10-29

1997-09-01 Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh

2007-10-29 Application granted granted Critical

2007-10-29 Publication of DK0925069T3 publication Critical patent/DK0925069T3/da

Links

206010020880 Hypertrophy Diseases 0.000 title 1
206010060862 Prostate cancer Diseases 0.000 title 1
208000000236 Prostatic Neoplasms Diseases 0.000 title 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 title 1
229960003230 cetrorelix Drugs 0.000 title 1
108700008462 cetrorelix Proteins 0.000 title 1
210000002307 prostate Anatomy 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK97944818T 1996-09-12 1997-09-01 Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer DK0925069T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2599096P	1996-09-12	1996-09-12
US4322897P	1997-04-10	1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en)	1996-09-12	1997-09-01	Means for treating prostate hypertrophy and prostate cancer

Publications (1)

Publication Number	Publication Date
DK0925069T3 true DK0925069T3 (da)	2007-10-29

Family

ID=26700570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97944818T DK0925069T3 (da)	1996-09-12	1997-09-01	Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer

Country Status (28)

Country	Link
US (4)	US6054432A (da)
EP (1)	EP0925069B1 (da)
JP (1)	JP2001500500A (da)
KR (1)	KR100546235B1 (da)
CN (1)	CN1126566C (da)
AR (1)	AR009757A1 (da)
AT (1)	ATE370743T1 (da)
AU (1)	AU738306B2 (da)
BR (1)	BR9713197A (da)
CA (1)	CA2215015A1 (da)
CZ (1)	CZ298738B6 (da)
DE (1)	DE69738045T2 (da)
DK (1)	DK0925069T3 (da)
EE (1)	EE04000B1 (da)
ES (1)	ES2289764T3 (da)
HU (1)	HUP0000261A3 (da)
IL (3)	IL128331A0 (da)
IS (1)	IS4978A (da)
MX (1)	MXPA99002420A (da)
NO (1)	NO326207B1 (da)
NZ (1)	NZ334540A (da)
PL (1)	PL193184B1 (da)
PT (1)	PT925069E (da)
RU (1)	RU2215537C2 (da)
SK (1)	SK286174B6 (da)
TR (1)	TR199900556T2 (da)
TW (1)	TWI224002B (da)
WO (1)	WO1998010781A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) *	1997-09-11	1999-03-12	Synthelabo	Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) *	1998-06-26	2003-06-11	Yamanouchi Pharma Co Ltd	Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) *	1999-03-17	2006-03-30	Zentaris Gmbh	LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7151100B1 (en)	1999-07-23	2006-12-19	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7129262B2 (en) *	1999-07-23	2006-10-31	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7105560B1 (en)	1999-07-23	2006-09-12	The Regents Of The University Of California	Use of etodolac in the treatment of multiple myeloma
US7361680B2 (en) *	1999-07-23	2008-04-22	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US6545034B1 (en) *	1999-07-23	2003-04-08	The Regents Of The University Of California	Use of etodolac for the treatment of chronic lymphocytic leukemia
TR200102583T2 (tr) *	1999-08-09	2002-07-22	Yamanouchi Pharmaceutical Co., Ltd.	Alt idrar yolları semptomlarının tedavisine yönelik farmasötik bileşim.
PT1955700E (pt)	1999-09-30	2011-05-04	Harbor Biosciences Inc	Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
US20040152672A1 (en) *	2000-08-09	2004-08-05	Carson Dennis A.	Indole compounds useful for the treatment of cancer
DE10040700A1 (de) *	2000-08-17	2002-02-28	Asta Medica Ag	Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
KR100876538B1 (ko) *	2000-08-17	2008-12-31	아에테르나 젠타리스 게엠베하	Ｌｈｒｈ 길항제의 염의 제조방법
JP2001288115A (ja) *	2001-02-07	2001-10-16	Yamanouchi Pharmaceut Co Ltd	下部尿路症治療剤
DE10137174A1 (de) *	2001-07-31	2003-02-13	Zentaris Ag	Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
WO2004026116A2 (en) *	2002-09-19	2004-04-01	The Regents Of The University Of California	Use of etodoclac to treat hyperplasia
GB0301016D0 (en) *	2003-01-16	2003-02-19	Univ London	Treatment of benign prostatic hyperplasia
EP1592430A4 (en)	2003-01-17	2006-05-31	Threshold Pharmaceuticals Inc	TREATMENT OF GOOD PROSTATE HYPERPLASIA BY MEANS OF ENERGYSTIC ACTIVE SUBSTANCES
AU2007248533B2 (en) *	2006-05-03	2012-03-15	Wisconsin Alumni Research Foundation	NL, N4-bis (buta-1, 3-dienyl) butane-1, 4-diamine pharmaceutical compositions and uses thereof
EP1891964A1 (en) *	2006-08-08	2008-02-27	AEterna Zentaris GmbH	Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) *	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) *	2008-02-29	2009-09-02	AEterna Zentaris GmbH	Use of LHRH antagonists at non-castrating doses
US10585101B2 (en)	2016-03-10	2020-03-10	Wavesense, Inc.	Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2465486A1 (fr) *	1979-09-21	1981-03-27	Roussel Uclaf	Nouvelle application utilisant la lh-rh ou des agonistes
HU199694B (en) *	1988-05-10	1990-03-28	Innofinance Altalanos Innovaci	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) *	1989-06-07	1990-12-13	Boehringer Mannheim Gmbh	Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101243A (en) *	1991-03-20	1999-12-22	Merck & Co Inc	Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
IL101245A0 (en) *	1991-03-20	1992-11-15	Merck & Co Inc	Pharmaceutical compositions for the treatment of prostatic cancer
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

1997
- 1997-08-07 US US08/908,198 patent/US6054432A/en not_active Expired - Fee Related
- 1997-09-01 HU HU0000261A patent/HUP0000261A3/hu unknown
- 1997-09-01 DK DK97944818T patent/DK0925069T3/da active
- 1997-09-01 EP EP97944818A patent/EP0925069B1/en not_active Expired - Lifetime
- 1997-09-01 WO PCT/EP1997/004740 patent/WO1998010781A1/en not_active Ceased
- 1997-09-01 PT PT97944818T patent/PT925069E/pt unknown
- 1997-09-01 AU AU46198/97A patent/AU738306B2/en not_active Ceased
- 1997-09-01 EE EEP199900121A patent/EE04000B1/xx not_active IP Right Cessation
- 1997-09-01 CZ CZ80899A patent/CZ298738B6/cs not_active IP Right Cessation
- 1997-09-01 SK SK301-99A patent/SK286174B6/sk not_active IP Right Cessation
- 1997-09-01 KR KR1019997002053A patent/KR100546235B1/ko not_active Expired - Lifetime
- 1997-09-01 TR TR1999/00556T patent/TR199900556T2/xx unknown
- 1997-09-01 AT AT97944818T patent/ATE370743T1/de not_active IP Right Cessation
- 1997-09-01 IL IL12833197A patent/IL128331A0/xx unknown
- 1997-09-01 MX MXPA99002420A patent/MXPA99002420A/es unknown
- 1997-09-01 RU RU99107280/14A patent/RU2215537C2/ru not_active IP Right Cessation
- 1997-09-01 BR BR9713197-0A patent/BR9713197A/pt not_active Application Discontinuation
- 1997-09-01 NZ NZ334540A patent/NZ334540A/xx unknown
- 1997-09-01 DE DE69738045T patent/DE69738045T2/de not_active Expired - Lifetime
- 1997-09-01 CN CN97197904A patent/CN1126566C/zh not_active Expired - Fee Related
- 1997-09-01 JP JP10513204A patent/JP2001500500A/ja active Pending
- 1997-09-01 ES ES97944818T patent/ES2289764T3/es not_active Expired - Lifetime
- 1997-09-01 PL PL332085A patent/PL193184B1/pl not_active IP Right Cessation
- 1997-09-10 CA CA002215015A patent/CA2215015A1/en not_active Abandoned
- 1997-09-10 TW TW086113121A patent/TWI224002B/zh active
- 1997-09-11 AR ARP970104168A patent/AR009757A1/es not_active Application Discontinuation
1998
- 1998-04-09 US US09/057,458 patent/US5998377A/en not_active Expired - Fee Related
- 1998-04-20 US US09/062,704 patent/US6071882A/en not_active Expired - Fee Related
1999
- 1999-02-02 IL IL128331A patent/IL128331A/en not_active IP Right Cessation
- 1999-02-16 IS IS4978A patent/IS4978A/is unknown
- 1999-03-11 NO NO19991192A patent/NO326207B1/no not_active IP Right Cessation
- 1999-09-22 US US09/401,851 patent/US6300313B1/en not_active Expired - Fee Related
2008
- 2008-01-30 IL IL189132A patent/IL189132A0/en unknown

Also Published As

Publication number	Publication date
DE69738045T2 (de)	2008-05-15
EE04000B1 (et)	2003-04-15
US5998377A (en)	1999-12-07
DE69738045D1 (de)	2007-10-04
US6054432A (en)	2000-04-25
IL189132A0 (en)	2008-06-05
ES2289764T3 (es)	2008-02-01
SK286174B6 (sk)	2008-04-07
HUP0000261A2 (hu)	2000-10-28
US6300313B1 (en)	2001-10-09
ATE370743T1 (de)	2007-09-15
PL193184B1 (pl)	2007-01-31
PL332085A1 (en)	1999-08-30
NO991192D0 (no)	1999-03-11
WO1998010781A1 (en)	1998-03-19
AU4619897A (en)	1998-04-02
RU2215537C2 (ru)	2003-11-10
CZ80899A3 (cs)	1999-11-17
CN1126566C (zh)	2003-11-05
BR9713197A (pt)	2000-04-04
TWI224002B (en)	2004-11-21
CZ298738B6 (cs)	2008-01-09
CA2215015A1 (en)	1998-03-12
HUP0000261A3 (en)	2001-03-28
EP0925069B1 (en)	2007-08-22
KR20010029495A (ko)	2001-04-06
NO326207B1 (no)	2008-10-20
JP2001500500A (ja)	2001-01-16
HK1021937A1 (en)	2000-07-21
AU738306B2 (en)	2001-09-13
MXPA99002420A (es)	2004-08-27
US6071882A (en)	2000-06-06
TR199900556T2 (xx)	1999-07-21
CN1230121A (zh)	1999-09-29
KR100546235B1 (ko)	2006-01-26
IL128331A0 (en)	2000-01-31
NZ334540A (en)	2000-07-28
PT925069E (pt)	2007-10-17
EP0925069A1 (en)	1999-06-30
NO991192L (no)	1999-04-28
AR009757A1 (es)	2000-05-03
EE9900121A (et)	1999-10-15
IL128331A (en)	2010-05-31
IS4978A (is)	1999-02-16
SK30199A3 (en)	2000-03-13

Publication	Publication Date	Title
DK0925069T3 (da)	2007-10-29	Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
IS2012B (is)	2005-05-13	Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
NO994069D0 (no)	1999-08-24	Forbindelser for immunoterapi av prostatacancer og fremgangsmåte for anvendelse derav
DE60023982D1 (de)	2005-12-22	System zur Behandlung von benigner Prostatahyperplasie
DK0942754T3 (da)	2003-08-04	Konjugater anvendelige til behandlingen af prostatacancer
AU3011299A (en)	1999-10-18	Combination therapy for the treatment of benign prostatic hyperplasia
AU2235395A (en)	1995-10-23	Biological markers of benign prostate hyperplasia
NO980718D0 (no)	1998-02-20	Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer
IS5502A (is)	2000-05-19	Samtengd efnasambönd nytsamleg við meðhöndlun á krabbameini í blöðruhálskirtli
FR2748874B1 (fr)	2000-11-10	Amplificateur et telephone portable l'utilisant
PT984777E (pt)	2004-01-30	Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
ZA982819B (en)	1999-10-04	Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
DK1054868T3 (da)	2003-12-22	Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
NO20012667D0 (no)	2001-05-30	Fremgangsmåte for aktivering av vann og anvendelse av aktivert vann av denne type
KR950700746A (ko)	1995-02-20	양성 전립선 비대를 치료하는 조성물 및 방법(Compositions and Methods For Treating Benign Prostatic Hypertrophy)
AU9128998A (en)	1999-03-22	Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
NO985695D0 (no)	1998-12-04	Formulering og fremgangsmÕte for Õ behandle kongrestiv hjerteinfarkt
ZA991319B (en)	2000-11-20	Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
SI0925069T1 (sl)	2007-10-31	Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka
BR9608912A (pt)	1999-03-02	Agonistas de meletonina para o tratamento de hiperplasia prostática benigna
ZA978162B (en)	1998-03-03	Means for treating prostate hypertrophy and prostate cancer.
GB9602903D0 (en)	1996-04-10	Conjugates useful in the treatment of benign prostatic hyperplasia
AU2003204320A1 (en)	2003-06-19	Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
ZA979655B (en)	1998-04-30	Conjugates useful in the treatment of prostate cancer.
GB9810895D0 (en)	1998-07-22	Combination therapy for the treatment of benign prostatic hyperplasia